101 related articles for article (PubMed ID: 8022201)
1. The C.B.17 scid mouse strain as a model for human disseminated leukaemia and myeloma in vivo.
Cattan AR; Douglas E
Leuk Res; 1994 Jul; 18(7):513-22. PubMed ID: 8022201
[TBL] [Abstract][Full Text] [Related]
2. A comparison of a CB17 scid mouse model and the tetrazolium-dye assay using human haematological tumour cell lines.
Cattan AR; Maung ZT
Cancer Chemother Pharmacol; 1996; 38(6):548-52. PubMed ID: 8823497
[TBL] [Abstract][Full Text] [Related]
3. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD
PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011
[TBL] [Abstract][Full Text] [Related]
4. BCL-2 expression by leukaemic blasts in a SCID mouse model of biphenotypic leukaemia associated with the t(4;11)(q21;q23) translocation.
Pocock CF; Malone M; Booth M; Evans M; Morgan G; Greil J; Cotter FE
Br J Haematol; 1995 Aug; 90(4):855-67. PubMed ID: 7669664
[TBL] [Abstract][Full Text] [Related]
5. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
[TBL] [Abstract][Full Text] [Related]
6. The use of animal models in multiple myeloma.
Libouban H
Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
[TBL] [Abstract][Full Text] [Related]
7. The SCID mouse environment causes immunophenotypic changes in human immature T-cell lines.
Uittenbogaart CH; Anisman DJ; Tary-Lehmann M; Vollger LW; Breit TM; Van Dongen JJ; Saxon A
Int J Cancer; 1994 Feb; 56(4):546-51. PubMed ID: 8112890
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a bioluminescent imaging-based in vivo leukemia model by intra-bone marrow injection.
Lee MW; Kim HJ; Yoo KH; Kim DS; Yang JM; Kim HR; Noh YH; Baek H; Kwon H; Son MH; Lee SH; Cheuh HW; Jung HL; Sung KW; Koo HH
Int J Oncol; 2012 Dec; 41(6):2047-56. PubMed ID: 23007607
[TBL] [Abstract][Full Text] [Related]
9. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease.
Huang YW; Richardson JA; Tong AW; Zhang BQ; Stone MJ; Vitetta ES
Cancer Res; 1993 Mar; 53(6):1392-6. PubMed ID: 8443818
[TBL] [Abstract][Full Text] [Related]
10. A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease.
Paton-Hough J; Chantry AD; Lawson MA
Bone; 2015 Aug; 77():57-68. PubMed ID: 25868800
[TBL] [Abstract][Full Text] [Related]
11. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
12. Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation.
Turner JH; Claringbold PG; Manning LS; O'Donoghue HL; Berger JD; Glancy RJ
J Natl Cancer Inst; 1993 Sep; 85(18):1508-13. PubMed ID: 8360933
[TBL] [Abstract][Full Text] [Related]
13. The SCID mouse as a model for multiple myeloma.
Ahsmann EJ; van Tol MJ; Oudeman-Gruber J; Lokhorst H; Uytdehaag FG; Schuurman HJ; Bloem AC
Br J Haematol; 1995 Feb; 89(2):319-27. PubMed ID: 7873382
[TBL] [Abstract][Full Text] [Related]
14. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
[TBL] [Abstract][Full Text] [Related]
15. Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system.
Huang SY; Tien HF; Su FH; Hsu SM
Am J Pathol; 2004 Feb; 164(2):747-56. PubMed ID: 14742278
[TBL] [Abstract][Full Text] [Related]
16. Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice.
Tong AW; Huang YW; Zhang BQ; Netto G; Vitetta ES; Stone MJ
Anticancer Res; 1993; 13(3):593-7. PubMed ID: 8391243
[TBL] [Abstract][Full Text] [Related]
17. The SCID-hu myeloma model.
Epstein J; Yaccoby S
Methods Mol Med; 2005; 113():183-90. PubMed ID: 15968103
[TBL] [Abstract][Full Text] [Related]
18. Animal models: Towards a myeloma mouse.
DeWeerdt S
Nature; 2011 Dec; 480(7377):S38-9. PubMed ID: 22169799
[No Abstract] [Full Text] [Related]
19. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.
Yamashita K; Iwasaki T; Tsujimura T; Sugihara A; Yamada N; Ueda H; Okamura H; Futani H; Maruo S; Terada N
Oncol Rep; 2002; 9(6):1237-44. PubMed ID: 12375027
[TBL] [Abstract][Full Text] [Related]
20. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
